S.4467 - MMEDS Act of 2020116th Congress (2019-2020)
|Sponsor:||Sen. Rubio, Marco [R-FL] (Introduced 08/06/2020)|
|Committees:||Senate - Finance|
|Latest Action:||Senate - 08/06/2020 Read twice and referred to the Committee on Finance. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: S.4467 — 116th Congress (2019-2020)All Information (Except Text)
Introduced in Senate (08/06/2020)
Medical Manufacturing, Economic Development, and Sustainability Act of 2020 or the MMEDS Act of 2020
This bill provides incentives for relocating medical manufacturing facilities in the United States and for manufacturing medical products (i.e., drugs and devices) in economically distressed zones. Specifically, the bill allows a income tax credit for 40% of the sum of wages paid in a medical product manufacturing economically distressed zone, employee fringe benefit expenses, and depreciation and amortization allowances with respect to qualified medical product manufacturing facility property, and a credit for economically distressed zone products and services acquired by domestic medical product manufacturers..
The bill also directs the Department of Health and Human Services to study the extent to which the health of aging individuals and vulnerable populations have been disproportionately harmed by the COVID-19 (i.e., coronavirus disease 2019) pandemic and prior epidemics and pandemics.